Showing results (151-160 of 190) with videos related to
Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2020
A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung CancerTina Cascone, Boris Sepesi, Heather Y Lin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2021
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and NeckRenata Ferrarotto, Moran Amit, Priyadharsini Nagarajan, et al.The Journal of Investigative Dermatology|October 1, 2014
The genomic landscape of childhood and adolescent melanomaCharles Lu, Jinghui Zhang, Panduka Nagahawatte, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 13, 2017
Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors, Mona Kamal, David I Rosenthal, et al.Scientific Data|November 10, 2021
Whole genome and exome sequencing reference datasets from a multi-center and cross-platform benchmark studyYongmei Zhao, Li Tai Fang, Tsai-Wei Shen, et al.Journal of the American Geriatrics Society|August 6, 2022
Effect of the STRIDE fall injury prevention intervention on falls, fall injuries, and health-related quality of lifeDavid A Ganz, Anita H Yuan, Erich J Greene, et al.Nature|January 13, 2012
A novel retinoblastoma therapy from genomic and epigenetic analysesJinghui Zhang, Claudia A Benavente, Justina McEvoy, et al.Nature Communications|April 13, 2022
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapySang T Kim, Yanshuo Chu, Mercy Misoi, et al.Journal for Immunotherapy of Cancer|October 24, 2024
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancerNicolas Zhou, Cheuk H Leung, William N William, et al.Signal Transduction and Targeted Therapy|February 21, 2022
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.Pageof 19